Summit Therapeutics Stock News

Penny stocks for your September watch list. The post 4 Penny Stocks To Watch For September 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

The biotech's recent upward momentum is showing no signs of fading.

Check these tips out for investing in penny stocks in September 2022 The post Investing in Penny Stocks in September? 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS

Investors responded enthusiastically to key insider buying.

The Dow Jones dropped by around 170 points on Wednesday following the release of Fed minutes. Investors, meanwhile, focused on some notable insider trades.

Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutics field Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutic

Cambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the C

Summit Therapeutics Inc (SMMT) shares closed today 14.8% higher than it did at the end of yesterday. The stock is currently down 35.5% year-to-date, down 46.8% over the past 12 months, and down 11.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $5.03 and as low as $2.23 this week.Shares closed 75.4% below its 52-week high and 35.9% above its 52-week low.Trading volume this week was 1.0% higher than the 10-day average and 132.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 107.7% The company's stock price performance over the past 12 months lags the peer average by 154.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available on Seeking Alpha, iTunes, Stitcher and Spotify. U.S.

Summit Therapeutics Inc (SMMT) shares closed today 14.8% higher than it did at the end of yesterday. The stock is currently down 35.5% year-to-date, down 48.9% over the past 12 months, and down 11.9% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $5.03 and as low as $2.23 this week.Shares closed 75.4% below its 52-week high and 35.9% above its 52-week low.Trading volume this week was 14.5% higher than the 10-day average and 132.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 105.7% The company's stock price performance over the past 12 months lags the peer average by 174.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The company just revealed disappointing phase 3 trial results for its only clinical-stage drug candidate.

Summit Therapeutics Inc (NASDAQ: SMMT) shares are trading lower after disappointing results from the Phase 3 Ri-CoDIFy study of ridinilazole for C. difficile infection (CDI).

Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study evaluat